Summary: Cigna Healthcare modified its genetic testing for reproductive carrier screening and prenatal diagnosis coverage policy (policy 0514), effective May 16, 2026. Here's what billing teams need to do.
Cigna Healthcare updated policy 0514 governing genetic testing for reproductive carrier screening and prenatal diagnosis. This coverage policy affects obstetrics, maternal-fetal medicine, genetics, and gynecology practices that bill Cigna for carrier screening and prenatal diagnostic testing. The policy document does not list specific CPT or HCPCS codes in the data available, so your billing team should pull the full policy text directly from Cigna to confirm which codes apply to your service mix before the May 16, 2026 effective date.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Cigna Healthcare |
| Policy | Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis |
| Policy Code | 0514 |
| Change Type | Modified |
| Effective Date | 2026-05-16 |
| Impact Level | High |
| Specialties Affected | Obstetrics, Maternal-Fetal Medicine, Medical Genetics, Gynecology, Reproductive Endocrinology |
| Key Action | Pull the full 0514 policy text, confirm which carrier screening and prenatal testing codes are covered under the updated medical necessity criteria, and update your prior authorization workflows before May 16, 2026 |
Cigna Genetic Testing for Reproductive Carrier Screening and Prenatal Diagnosis Coverage Criteria and Medical Necessity Requirements 2026
Genetic testing billing is one of the highest-denial-risk categories in the lab and genetics space. Cigna's 0514 policy sits at the center of that risk for any practice serving patients of reproductive age.
The Cigna genetic testing for reproductive carrier screening and prenatal diagnosis coverage policy covers two distinct clinical categories. The first is carrier screening — testing that identifies whether a patient or their partner carries a genetic variant that could cause disease in offspring. The second is prenatal diagnosis — testing performed during pregnancy to detect chromosomal or genetic conditions in the fetus.
Cigna evaluates medical necessity separately for each category. That matters for billing because a test that clears the carrier screening criteria will not automatically clear the prenatal diagnosis criteria. Your team should treat these as two separate coverage buckets, not one.
Carrier Screening
For carrier screening, Cigna's medical necessity criteria generally hinge on clinical indication, population-based guidelines, and whether the test is ordered before or during pregnancy. Preconception carrier screening has historically been covered for conditions where carrier frequency is high enough to meet population-based screening thresholds. Expanded carrier screening panels — those that test for dozens or hundreds of conditions simultaneously — have been an area of active policy scrutiny across all major payers, and Cigna is no exception.
Whether a specific panel qualifies under this coverage policy depends on how Cigna defines the conditions as meeting established clinical guidelines. Panels not tied to professional society guidance from ACOG, ACMG, or SMFM often run into experimental or investigational designations. If your lab or practice bills expanded carrier panels, this modified policy may shift which panels clear medical necessity review.
Prenatal Diagnosis
Prenatal diagnosis testing includes procedures like chorionic villus sampling (CVS), amniocentesis, and cell-free fetal DNA (cfDNA) testing — also called non-invasive prenatal testing (NIPT). Cigna's prior authorization requirements for prenatal genetic testing have historically been tied to maternal age, family history, abnormal first-trimester screening results, or other defined clinical risk factors.
The prior authorization trigger is where most claim denials in this category originate. If a test is ordered without documented medical necessity criteria that match the policy — or without obtaining prior auth when Cigna requires it — the claim fails. Make sure your authorization workflow is current with the May 16, 2026 updates before the first claims go out under the new policy.
Cigna Genetic Testing Exclusions and Non-Covered Indications
Cigna's reproductive genetic testing policies have historically excluded or designated as experimental certain categories of testing. Based on the structure of policy 0514 and standard Cigna coverage policy patterns in this space, your team should specifically watch for non-coverage designations in these areas.
Whole exome sequencing (WES) and whole genome sequencing (WGS) ordered for prenatal diagnosis without a specific high-risk indication — such as a known pathogenic variant in the family or multiple fetal anomalies — have historically been experimental under Cigna policies. Cigna has also applied non-covered designations to preimplantation genetic testing (PGT) in some plan types, particularly self-funded plans with infertility exclusions.
Expanded carrier screening panels that include conditions with very low carrier frequency or no established treatment pathway have been scrutinized under Cigna's medical necessity framework. The real issue here is that payers including Cigna draw a line between medically actionable screening and testing that doesn't change clinical management. Tests that fall on the wrong side of that line get denied.
Because this post does not have the full 0514 policy text available, and specific exclusions in the modified version may have shifted, confirm every non-coverage category directly from the Cigna source document before May 16, 2026. If your practice bills high volumes of expanded panels or NIPT for average-risk patients, loop in your compliance officer now.
Coverage Indications at a Glance
The policy document available does not include a code-level breakdown of individual indications with confirmed coverage status. The table below reflects the general coverage framework typical of Cigna policy 0514 and should be verified against the full policy text before use in billing workflows.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Carrier screening for conditions with established population-based guidelines (e.g., cystic fibrosis, spinal muscular atrophy, fragile X) | Generally Covered | Confirm with Cigna 0514 policy | Medical necessity documentation required |
| Expanded carrier screening panels meeting ACMG/ACOG guideline thresholds | Likely Covered (criteria-dependent) | Confirm with Cigna 0514 policy | May require prior authorization; panel scope matters |
| Expanded carrier screening panels outside professional society guidelines | Likely Not Covered / Experimental | Confirm with Cigna 0514 policy | High denial risk without strong clinical documentation |
| NIPT/cfDNA for high-risk pregnancies (advanced maternal age, prior affected pregnancy, abnormal screen) | Generally Covered | Confirm with Cigna 0514 policy | Prior authorization often required |
| NIPT/cfDNA for average-risk pregnancies | Coverage Varies by Plan | Confirm with Cigna 0514 policy | Plan-level differences; self-funded plans may exclude |
| Chorionic villus sampling (CVS) with documented clinical indication | Generally Covered | Confirm with Cigna 0514 policy | Prior authorization may apply |
| Amniocentesis with documented clinical indication | Generally Covered | Confirm with Cigna 0514 policy | Prior authorization may apply |
| Whole exome/genome sequencing for prenatal diagnosis without high-risk indication | Likely Experimental | Confirm with Cigna 0514 policy | Strong documentation required if billed |
| Preimplantation genetic testing (PGT) | Coverage Varies by Plan | Confirm with Cigna 0514 policy | Often excluded in self-funded plans with infertility carve-outs |
Every row in this table needs verification against the actual 0514 policy text. Do not use this table as a substitute for reviewing the Cigna source document.
Cigna Genetic Testing Billing Guidelines and Action Items 2026
Genetic testing reimbursement from Cigna requires clean documentation, accurate coding, and prior authorization on the front end. The modified 0514 policy raises the stakes on all three. Here's what your team does now.
| # | Action Item |
|---|---|
| 1 | Pull the full Cigna 0514 policy text before May 15, 2026. The effective date is May 16, 2026. You need the updated document in hand at least one day before claims start generating under the new criteria. Access it at app.payerpolicy.org/p/cigna/mm_0514_coveragepositioncriteria_genetic_testing_repro_carrier_prenatal or directly from Cigna's provider portal. |
| 2 | Run a line-by-line comparison between the prior and current 0514 policy. Modified policies change coverage criteria in ways that aren't always obvious from the title. A phrase shift from "covered when" to "covered only when" is enough to flip a claim from paid to denied. If your team doesn't have the prior version, contact your Cigna provider relations rep to get it. |
| 3 | Audit your prior authorization triggers for all reproductive genetic testing codes. Prior authorization requirements are the number one source of claim denial in genetic testing billing. Confirm whether any new test types or indications now require prior auth under the updated policy. Update your scheduling and order-entry workflows before May 16, 2026 so auth requests go out before testing happens — not after. |
| 4 | Review your medical necessity documentation templates. Cigna's coverage policy for reproductive carrier screening and prenatal diagnosis ties reimbursement to documented clinical indication. Update your ordering provider templates, EHR order sets, and pre-authorization request forms to capture the specific criteria Cigna now requires. Vague documentation — "patient requested testing" or "family history of genetic conditions" without specifics — will generate denials. |
| 5 | Identify your highest-volume reproductive genetic testing codes and check each one against the updated policy. Even without a code list in this post, your billing team knows which codes drive the most volume. Pull your top 10 codes from claims data, then map each one to the 0514 criteria. Codes that were covered under the old policy may now require additional documentation, prior auth, or may have shifted to experimental status. |
| 6 | Flag self-funded Cigna plans separately. Self-funded (ASO) plans can carve out or expand coverage beyond Cigna's standard policy. Reproductive genetic testing — especially NIPT for average-risk patients and preimplantation genetic testing — is a common area for plan-level differences. Check the specific plan documents for your highest-volume self-funded accounts. If you're not sure how to do that, your Cigna provider relations rep can help. |
| 7 | Talk to your compliance officer if your lab or practice bills expanded carrier panels at high volume. The medical necessity framework for expanded panels is where this type of policy change most often bites practices. Your compliance officer should review the updated 0514 criteria against your current billing patterns before the effective date. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Reproductive Carrier Screening and Prenatal Diagnosis Under Cigna Policy 0514
The policy data available for this post does not include a specific code list from Cigna's 0514 policy document. Do not use fabricated or assumed codes for billing under this policy.
Your billing team should retrieve the complete code list directly from the Cigna policy source. Reproductive genetic testing typically involves CPT codes from the Tier 1 and Tier 2 molecular pathology sections, as well as genomic sequencing procedure codes — but the specific codes covered, excluded, or designated experimental under the updated 0514 policy must come from Cigna's own documentation.
Once you have the full policy text, organize your code review by coverage status: covered when criteria are met, covered with prior authorization, and not covered or experimental. That structure will make it easier to update your charge capture and denial management workflows.
If your coding team needs help mapping the policy criteria to the correct molecular pathology CPT codes, a genetics-specialized billing consultant is worth the conversation — especially if your volume in this category is high.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.